This combination not only helps in reducing the tumor burden but also addresses one of the most challenging aspects of cancer therapy—immune evasion by the tumor.409 OVs counteract tumor manipulation of immune checkpoints, such as PD-L1,410,411 and CTLA-4,412,413 which tumors use to evade immune surveillance. The gene discussed is CTLA4; the disease is cancer.